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Abstract
Background: Most adults with diabetes who are at high risk for complications have family or friends who are
involved in their medical and self-care (“family supporters”). These family supporters are an important resource who
could be leveraged to improve patients’ engagement in their care and patient health outcomes. However,
healthcare teams lack structured and feasible approaches to effectively engage family supporters in patient self-
management support. This trial tests a strategy to strengthen the capacity of family supporters to help adults with
high-risk diabetes engage in healthcare, successfully enact care plans, and lower risk of diabetes complications.
Methods/design: We will conduct a randomized trial evaluating the CO-IMPACT (Caring Others Increasing
EnageMent in Patient Aligned Care Teams) intervention. Two hunded forty adults with diabetes who are at high
risk for diabetes complications due to poor glycemic control or high blood pressure will be randomized, along with
a family supporter (living either with the patient or remotely), to CO-IMPACT or enhanced usual primary care for
12 months. CO-IMPACT provides patient-supporter dyads: it provides one coaching session addressing supporter
techniques for helping patients with behavior change motivation, action planning, and proactive communication
with healthcare providers; biweekly automated phone calls to prompt dyad action on new patient health concerns;
phone calls to prompt preparation for patients’ primary care visits; and primary care visit summaries sent to both
patient and supporter. Primary outcomes are changes in patient activation, as measured by the Patient Activation
Measure-13, and change in 5-year cardiac event risk, as measured by the United Kingdom Prospective Diabetes
Study cardiac risk score for people with diabetes. Secondary outcomes include patients’ diabetes self-management
behaviors, diabetes distress, and glycemic and blood pressure control. Measures among supporters will include use
of effective support techniques, burden, and distress about patient’s diabetes care.
Discussion: If effective in improving patient activation and diabetes management, CO-IMPACT will provide
healthcare teams with evidence-based tools and techniques to engage patients’ available family or friends in
supporting patient self-management, even if they live remotely. The core skills addressed by CO-IMPACT can be
used by patients and their supporters over time to respond to changing patient health needs and priorities.
Trial registration: ClinicalTrials.gov, NCT02328326. Registered on 31 December 2014.
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Background
The prevalence of diabetes in the USA is growing [1, 2],
and many adults with diabetes are at high risk for
diabetes complications due to uncontrolled risk factors
[3, 4]. Despite high-quality diabetes care delivery, 20–
30% of patients with diabetes have poor glycemic control
or poor blood pressure (BP) control [5]. Patients with
uncontrolled risk factors are at high risk for disabling
and costly diabetes complications, including stroke,
heart attack, amputation, kidney failure, or blindness. To
reduce diabetes complications, these “high-risk” patients
are given treatment regimens that are complicated and
often difficult to follow in day-to-day life. In addition,
these patients must effectively communicate and coord-
inate with multiple medical providers and proficiently
navigate the healthcare system. In light of these complex
care needs, high-risk patients often need more support
than the healthcare systems have the capacity to offer.
One relatively untapped resource for this support is a
patient’s natural social network of family and friends.
Three out of four adults with diabetes reach out to an un-
paid family member or friend (a “family supporter”) for
ongoing help with diabetes management [6, 7]. These sup-
porters assist patients in engaging in activities directly re-
lated to successful diabetes management, including
medication management and adherence, tracking home
glucose and BP measurements, maintaining a healthful
eating plan, and being physically active [6–8]. Family sup-
porters also often help patients make key decisions about
their diabetes management, such as how to address medi-
cation side effects [9]. Typically, 50–60% of family sup-
porters are spouses, and most of the rest are family
members who do not live with the patient (such as adult
children) [6, 10, 11]. Prior research has shown that chronic-
ally ill patients with low health literacy, multiple comorbidi-
ties, and comorbid depression involve family supporters in
their care more often [12–14].
Family and friend supporters are uniquely poised to pro-
vide personalized, frequent, and ongoing support for health
management. Trusted family supporters often already inter-
act frequently with patients in their home environment as
part of established long-term relationships. Family and
friends have unique vantage points to identify and under-
stand patients’ struggles with health management and then
intervene effectively. In fact, research studies have consist-
ently shown that chronically ill patients with family sup-
porters have better self-management and long-term health
outcomes [15–18]. For patients with diabetes, higher levels
of family support are linked with better glycemic control
and lower mortality [15]. In other chronic conditions that
require significant self-management, such as cardiac disease
and heart failure, higher levels of social support are linked
to lower rates of recurrent cardiac events and hospitaliza-
tions [16, 17]. There is strong evidence that social support
acts on chronic disease outcomes largely through improved
patient self-management behaviors (see the theoretical
model in Fig. 1) [19].
Recent Institute of Medicine reports on aging and care-
giving have concluded that family caregivers should be ex-
plicitly incorporated into healthcare delivery [20, 21]. Yet,
healthcare systems lack formal mechanisms to involve fam-
ily supporters in care. This is unfortunate, as these sup-
porters could play a crucial role in helping patients
effectively engage in behaviors to improve health. Increas-
ingly common team-based models of healthcare, such as
the patient-centered medical home (PCMH) — these
team-based models are known as Patient Aligned Care
Teams (PACT) — in the Veterans Health Administration
(VHA) [22], provide opportunities to expand our concept
of teamwork in healthcare to include not only allied health-
care professionals but also lay people such as family sup-
porters. Prior studies indicate that family supporters are
already highly involved in patients’ interactions with the
healthcare system. About half of patients with diabetes are
Fig. 1 Theoretical model
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regularly accompanied by a supporter in the exam room
for healthcare visits [12, 13], and 25% have had a supporter
talk on the phone with their clinician in the last year [12].
Importantly, family supporters often help patients prepare
questions before healthcare visits, assist patients in pro-
cessing information and plans (“debriefing”) after visits,
and help patients navigate health system services such as
pharmacy fills and diabetes class enrollment [23].
Previous interventions aiming to leverage family support
to improve disease management have generally engaged
supporters in patients’ day-to-day health management
through counseling or coaching [24, 25]. Such interven-
tions have demonstrated improvements in dietary behav-
ior among patients with heart failure [26] and physical
activity among obese patients [27]. However, no published
interventions or clinical programs we are aware of have
focused on helping family supporters boost chronically ill
patients’ engagement in clinical care and medical self-care
(e.g., medication adherence).
One promising lever for helping family supporters be
more effective at improving patient health is by training
them to boost patient activation. “Activated” patients are
those who have the “skills and confidence to become ac-
tively engaged in their health and healthcare” [28]. Acti-
vation includes the ability to share in decision-making
with healthcare providers, monitor and self-manage
symptoms, and access care in an appropriate and timely
way. Highly activated patients have better health behav-
iors (including adherence to medications, regular
self-monitoring at home, physical activity, and healthful
eating) and health outcomes (including lower body mass
index, hemoglobin A1c (HbA1c), BP, and cholesterol)
[29]. Increases in patient activation over time are linked
to improvements in similar health behaviors and out-
comes [30]. There are several reasons to hypothesize that
family supporters can help increase patient activation.
There are very strong links between social support and im-
proved patient self-efficacy for self-care [14, 31–34], a con-
cept closely related to patient activation. Higher social
support is linked to activated self-management behaviors,
such as increased self-monitoring [35, 36]. When sup-
porters accompany patients to medical visits, the patients
exhibit more activated behavior, including increased partici-
pation in decision-making with providers [10, 12, 13]. In
prior studies, patients participating with a family supporter
in an interactive voice response (IVR) self-management
intervention were more engaged in the intervention than
those who participated alone [37, 38].
There are several other promising methods to increase
the ability of family supporters to positively affect the
health of patients with diabetes. In our national survey
of 760 family supporters of patients with chronic disease
[39], supporters reported feeling limited by a lack of
patient-specific information, such as changes in
medication regimens or test results, as well as a lack of
health system-specific information, such as the roles of
healthcare team members or available diabetes programs
[9]. Supporters also face significant challenges when
helping patients prepare for, and debrief after, clinical
visits. For example, patients often do not bring written
questions for the doctor, and many are not confident
they are reporting accurate visit information back to
their supporter [23]. Twenty-eight percent of sup-
porters reported that their patient-partner regularly dis-
cusses being confused about healthcare provider
instructions [39]. Prior studies also indicate that family
supporters have been less effective at influencing pa-
tients’ medical self-management tasks (e.g., medication
adherence or blood glucose monitoring) than healthful
lifestyles (e.g., healthful eating) [19, 35, 40], and there-
fore family supporters may benefit from training fo-
cused on increasing their knowledge of and comfort
with medications and monitors.
Finally, family supporter effectiveness could also be
boosted through more structured and action-oriented
between-visit discussions with patients. In our national
family supporter survey, we found that supporters dis-
cuss health with their patient-partners almost every time
they talk, but approximately 30% were unsure what
questions to ask or what advice to give about diabetes
[9]. Supporters can make the most of these discussions
when they have patient-specific information and when
they use evidence-based support techniques, such as
positive and autonomy-supportive statements and col-
laborative action planning and coping [41].
We designed an intervention that incorporates these
promising evidence-based and stakeholder-informed
methods to increase family supporter effectiveness in
helping patients increase patient activation and manage
diabetes successfully. The intervention, called Caring
Others Increasing EngageMent in PACT (CO-IMPACT),
provides coaching, tools, and information to family sup-
porters and patients in the primary care setting. The over-
arching goal of this intervention is to structure and
facilitate family supporter involvement in healthcare so
that patients can become more actively engaged in their
care and improve their diabetes management and out-
comes. CO-IMPACT approaches family supporters as part
of the patient’s healthcare team, helping to support the pa-
tient in patient-led self-management. CO-IMPACT will
address key limitations to a supporter’s potential to be ef-
fective in this role by providing supporters with the fol-
lowing: ongoing information about their patient-partner’s
health status and treatment plan; ways to help patients
identify and engage in appropriate healthcare system
services; structured pre- and post-primary care visit in-
formation that can improve supporter-patient discus-
sions about diabetes plans; and guidance to supporters
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on evidence-based communication techniques such as
autonomy-supportive communication. The CO-IMPACT
approach does not focus on diabetes management educa-
tion, but instead focuses on underlying skills that family
supporters can use over time to help patients improve ac-
tivation in care and successful self-management of health
conditions.
We have designed CO-IMPACT so that it can be in-
corporated into care delivered by PCMH team members,
such as nurse care managers or health coaches, and to
take advantage of technology available to healthcare
teams, such as patient portals and mobile-health auto-
mated monitoring systems. Our central hypothesis is
that providing healthcare engagement tools to both
health supporters and patients will increase patient acti-
vation and improve management of diabetes complica-
tion risks. We will evaluate the impact of CO-IMPACT
on patient activation, patient health behaviors, and
physiologic changes in diabetes complication risk fac-
tors, while at the same time measuring the intervention’s
impact on family supporters.
Methods/design
Overall design and aims
This will be a randomized controlled trial evaluating the
superiority of the CO-IMPACT intervention over en-
hanced usual care. Two hundred forty patients with dia-
betes receiving primary care at the VHA who are at high
risk for diabetes complications and who have a family
supporter involved in their care (called the patient’s
“Care Partner”) will be recruited along with the family
supporter. Patients will be identified for recruitment
from a data warehouse containing VHA patient health
record data, and patient-supporter dyads will be ran-
domized to CO-IMPACT or usual PACT primary care.
Outcomes will be measured at baseline, 6 months, and
12 months post-enrollment via patient and supporter
surveys, and patient laboratory tests, vital signs, and
medical records. Figure 2 indicates the schedule of
standard protocol items, and Fig. 3 outlines the flow of
intervention components.
The study’s specific aims are to:
1. Determine the effect of the CO-IMPACT interven-
tion on patient engagement in treatment and on
health behaviors among patients at high risk for dia-
betes complications. We hypothesize that CO-
IMPACT will significantly increase patient activa-
tion, as measured by the Patient Activation
Measure-13 (PAM-13) compared to usual VA
PACT care.
2 Determine the effect of the CO-IMPACT interven-
tion on health risks among patients at high risk for
diabetes complications. We hypothesize that CO-
IMPACT will significantly decrease patients’ 5-year
cardiovascular event risk, as measured by the
United Kingdom Prospective Diabetes Study
(UKPDS) cardiac risk score (which includes HbA1c,
non-fasting lipid levels, and BP) [42] compared to
usual PACT care
3 Evaluate how the characteristics of patients, family
supporters, and their relationships mediate and
moderate the effects of CO-IMPACT. We
hypothesize that higher levels of family supporter
participation in CO-IMPACT intervention compo-
nents will lead to greater improvements in patient
activation and patient cardiac risk.
Setting
Participants will be recruited from among patients re-
ceiving care at two Veterans Affairs (VA) primary care
clinics. One is a large, multiprovider clinic linked with
a tertiary healthcare center; the other is a large,
free-standing, community-based outpatient clinic. The
study contacts will take place mainly via the Internet,
telephone, and mail, enhanced by an initial coaching
session in the outpatient clinic. The protocol is de-
signed at each stage to accommodate family supporters
who live with the patient, apart from but close to the
patient, or at a distance from the patient. These accom-
modations for family supporter participants include
phone-based recruitment, screening, and consent pro-
cesses, and Internet- and phone-based intervention par-
ticipation options [43].
Participants and recruitment
We will identify potentially eligible patients via the
VHA’s Corporate Data Warehouse (CDW), a national re-
pository of data extracted from VA electronic medical
record systems. Patients must be receiving care at one of
the recruitment sites and be between 30 and 70 years
old, as the study focuses on (1) family interactions
among mature adults rather than teens or those who
have had type 1 diabetes since their youth, and (2) goals
for reducing 5-year diabetes complication risk that might
be altered for more elderly patients with more limited
life expectancy or who are at higher risk from tighter
diabetes control. Eligible patients will have (1) a diagno-
sis of diabetes based on diagnoses from one inpatient or
two outpatient encounters, or a diabetes medication pre-
scription (at least one > 3-month prescription for insulin
or an oral diabetes medication other than metformin),
(2) a usual VA primary care provider (who is not a med-
ical resident/trainee nor a geriatric specialist) and at
least two visits to their usual VA primary care clinic in
the previous 12 months, (3) poor glycemic control (last
HbA1c within 9 months > 8%) or poor BP control. Poor
BP control is defined as (1) more than one BP reading in
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last 9 months: most recent systolic blood pressure
(SBP > =150 mmHg, and mean SBP over 9 months > =
150 mmHg; or (2) if only one BP reading in the last
9 months: last SBP in last 6 months > = 160 mmHg; or
(3) last diastolic BP or mean diastolic over 9 months not
<= 65 mmHg. If multiple BPs were recorded in 1 day,
the lowest one will be used. BPs recorded on days with
encounters in the emergency department, urgent care,
or surgical clinics; medical procedures; or inpatient days
will not be used to determine patient eligibility. Patients
will be excluded from the trial if they have a serious
mental illness (bipolar, schizophrenia, delusional disor-
ders, or other psychoses), dementia, moderate to pro-
found intellectual disability, or active substance abuse as
determined by encounter codes in a single inpatient or
outpatient encounter in the last 2 years.
Potentially eligible patients who meet the preceding
initial criteria will be sent an introductory letter inform-
ing them about the study and inviting them to learn
more about participating. The letter will give the partici-
pant a method for opting out of further contact. In the
absence of such notification, 7–10 days after the letter is
expected to arrive, study staff will call patients to explain
the study in more detail, conduct initial screening, and
ask eligible patients if they wish to participate.
Patients will be excluded if the screening call deter-
mines that they (1) do not plan to use VA primary care
as their main source of diabetes care over the subse-
quent 12 months; (2) are not able to use a telephone to
respond to twice monthly automated calls; (3) expect to
have a > 1-month gap in care from their usual primary
care site in the 12 months following enrollment (e.g.,
Fig. 2 Schedule of standard protocol items
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due to “snowbird” travel); (4) live in a nursing home or
assisted living facility; (5) have significant cognitive im-
pairment as measured by more than two of six possible
errors on the Callahan six-item screener to identify cog-
nitive impairment [44]; (6) need help with more than
one of the six basic activities of daily living (ADLs) as
measured by the Katz Index of Independence in ADLs
[45]; (7) are not fluent in English; (8) have a life-limiting
severe illness (end-stage renal disease (ESRD) requiring
dialysis, chronic obstructive pulmonary disease (COPD)
requiring oxygen, cancer undergoing active treatment, or
heart failure with New York Heart Association (NYHC)
III–IV symptoms); (9) are concurrently enrolled in an-
other research study or VA program, at time of enroll-
ment, that could conflict with CO-IMPACT’s protocol
(e.g., another diabetes management intervention); (10)
are concurrently enrolled in the VA Diabetes TeleHealth
program; (11) are currently pregnant or planning to be-
come pregnant in the next 12 months; or (12) are unable
to identify an eligible adult family member or friend who
is regularly involved in their health management or
healthcare who consents to participate in the study.
In the final screening question, the patient will be
asked “Do you have a family member or friend who gets
involved with your healthcare in one of these ways...”
followed by a list of specific support roles including help
with medications, help with home glucose test results,
tracking medical information, or coming to doctor’s ap-
pointments. In our preliminary studies, this question
performed equally well at identifying highly involved and
willing supporters as scoring multiple family members
on the more complex Norbeck Social Support Question-
naire [46] research measure. Family member participants
can either live with the patient or live separately. If the
patient names someone, he/she will be asked if the
family member meets the following criteria: (1) talks
with the patient about the patient’s health at least twice
monthly on average, (2) is at least 21 years old, (3)
speaks English fluently, (4) lives in the USA, and (5)
does not receive pay to provide care for the patient. If
the potential family supporter is deemed ineligible, the
patient will be asked to nominate another person to be
assessed for eligibility.
Eligible patients who identify a potentially eligible family
supporter will be encouraged to contact that family sup-
porter to explain their interest in the study, and concur-
rently, the family member will be sent a letter that
includes a study information sheet. After 1 week, a re-
search assistant will call the potential family supporter to
describe the study and assess interest and eligibility. Sup-
porters will be excluded if, via the screening questions,
they report that they (1) are younger than 21 years old; (2)
have ever been told by a doctor that they have dementia,
schizophrenia, or manic depression; or (3) receive pay for
caring for the patient. They will also be excluded if they
meet the following criteria, determined and defined in a
similar manner to that described above in the patient
screener: have significant cognitive impairment, need help
with basic activities of daily living, or have a life-limiting
severe illness. If the family member is interested and de-
termined to be eligible, he/she will provide informed con-
sent via phone.
Enrollment and randomization
Once the family supporter has provided verbal consent
over the phone and is enrolled as the patient’s Care Part-
ner, the patient will be asked to come to his/her usual
primary care clinic for in-person informed consent and
baseline study assessment (see the subsection Measures
and analysis). During this enrollment visit, the research
Fig. 3 Flow of intervention components
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assistant will offer participants home glucometers and
BP monitors if they would like them, but they are not re-
quired to have them. At the end of the visit, dyads will
be randomly assigned to the intervention or the en-
hanced usual care group using an online randomizer
that employs methods described by Pocock and Simon
[47]. Randomization of patient-Care Partner dyads will
be balanced across a single prognostic factor with two
levels: living with Care Partner and living apart from
Care Partner. Sampling rates will be equivalent (1:1)
across both levels of the balancing variable. The
minimization algorithm to balance treatment assignment
uses the range function. The level of determinism will be
set to 5 on a scale from 1 to 10 to increase balanced as-
signment of treatment condition while minimizing the
predictability of treatment assignment.
CO-IMPACT intervention
The intervention period will last 12 months. The
CO-IMPACT intervention will be delivered by a Dyad
Engagement Coach (DEC) and an automated IVR tele-
phone system (Fig. 3). The intervention content and de-
sign were developed from an earlier initial pilot version,
conducted over 6 months with 19 patient-Care Partner
pairs [48] who gave extensive feedback that was incorpo-
rated into the version used in this protocol.
Dyad Engagement Coach The DEC will be an individ-
ual with a background in health education. The DEC will
receive training from the study investigators in basic dia-
betes management; concepts underlying patient activa-
tion, motivational interviewing, action planning, and
autonomy-supportive communication; and techniques to
promote effective patient and supporter communication
with clinicians.
Initial coaching session Dyads will first attend one ini-
tial coaching session at their usual primary care clinic.
Patients will be asked to attend this session in person,
and Care Partners can attend in person or via speaker-
phone. Care Partners who participate by phone will be
pre-mailed printed materials and guided to the interven-
tion website during the session if possible. As shown in
the initial session agenda (Table 1), this session serves to
include supporters in the delivery of information that
patients typically receive on their own, and it adds
coaching in several skills that patients and family mem-
bers do not typically receive in usual care. The content
emphasizes roles the family can take in encouraging pa-
tients to make action plans and communicate effectively
with their healthcare teams. Care Partner use of
autonomy-supportive communication techniques with
patients is a key focus (see Additional file 1 for a selec-
tion from the coaching script). Dyads will be encouraged
to talk about diabetes weekly and given suggested con-
versation topics, including reviewing and adjusting pa-
tient action plans. During the session, participants will
be encouraged to work together on an initial diabetes
management goal and identify positive communication
techniques they would like to use during their weekly
conversations.
Materials available to participants After the initial ses-
sion, patients and Care Partners will be able to review the
guidelines and talking points discussed via a study website
and a printed handbook (see Additional files 2 and 3 for
excerpts from the handbook). These materials will include
general information about diabetes management that is
available in usual care, plus content on family supporter
communication with patients and providers. Care Partner
communication content is based on (1) content from the-
oretically based and effective research interventions, such
as an autonomy-supportive communication intervention
for family supporters of patients with heart failure [49],
and (2) guidelines for caregiver-clinician communication,
such as those produced by the National Family Caregivers
Association.
Between-visit action planning prompted by automated
telephone technology Throughout the 12-month inter-
vention, patient participants will receive IVR assessment
calls once every 2 weeks. IVR is an automated technol-
ogy that allows patients to report and receive informa-
tion via a touchtone telephone. Calls can be placed at
times convenient to the patient, and data are collected
when patients answer pre-recorded voice prompts [50].
The goal of these calls is to prompt continued action
planning and family supporter involvement between pri-
mary care visits. The core content is based on scripts de-
veloped by physicians, nurse educators, behavioral
specialists, and experts in mobile health. Calls will last
roughly 15 min, and content is guided by principles of
Table 1 Initial coaching session agenda
Review the patient’s diabetes complication risk status: last HbA1c, blood
pressure, lipid levels, smoking status, and calculated UKPDS 5-year car-
diac risk score
Review the patient’s latest diabetes plan based on medical record
progress notes and prescriptions
Coaching on dyadic approach to goal-setting and action planning
Coaching on use of positive and autonomy-supportive communication
Structured talking points for biweekly patient-supporter discussions
about diabetes and action planning
Educate dyad about members of the patient’s PACT teamlet, their roles,
and how to reach them
Educate dyad about diabetes risk reduction programs available in PACT
Techniques for effective and activated patient and supporter
communication with patients’ medical providers
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patient activation and family supporter engagement.
During each call, patients will be asked a series of ques-
tions to identify diabetes management concerns (see
Table 2) that they could focus on in creating action
plans. These include more than two fasting home glu-
cose readings over 200 mg/dl or one under 80 mg/dl,
two home SBP readings over 150 mmHg or any home
SBP readings < 100 mmHg, bothersome medication side
effects, running short on medication supply, or new foot
problems. If any concerning health issues are identified
during the call, following a patient empowerment ap-
proach, the patient will be asked whether he/she con-
siders the identified issue important to address over the
next 2 weeks. At the end of the call, the patient will be
reminded to make an action plan to address one or two
of these issues that he/she indicated as important. After
each completed IVR call, the Care Partner will receive
an automated structured email summarizing the call,
with any identified health issues, which issues the patient
considers important to address, and advice on how the
Care Partner can support the patient with identified is-
sues, including links to relevant content on the study web-
site (see Additional file 4 for a sample email message).
Emails will remind Care Partners to discuss diabetes care
with the patient using the autonomy-supportive tech-
niques discussed at the initial coaching session. The pa-
tient’s primary care team will receive an automated fax
alert when patients indicate clinically urgent issues during
their call (including ≥ 2 blood sugar readings < 70 mg/dl
or ≥ 1 blood sugar reading > 300 mg/dl, or ≥ 2 SBP read-
ings < 90 mmHg or ≥ 1 SBP reading > 170 mmHg).
Primary care visit preparation The patient’s DEC will
be alerted of the patient’s upcoming primary care visits
via an automated weekly scan of VA appointment re-
cords. A qualifying visit will be an in-person visit to a
primary care provider, nurse, or clinical pharmacist. Ap-
proximately 1 week before each qualifying visit, the DEC
will conduct a preparation session with the patient via
telephone. Using a visit preparation worksheet (see
Additional file 5), the DEC will help patients identify any
diabetes risk-related questions or concerns they would like
to address during their visit, as well as diabetes-related in-
formation, such as home monitoring logs, they will bring
to the visit. The DEC will invite patients to role-play, ask-
ing one or two questions most important to them. If a pa-
tient’s Care Partner is present with the patient at the time
of the call, the DEC will suggest that the patient invite the
Care Partner to participate in the call. Whether or not the
Care Partner participates in the call, the Care Partner will
be emailed or mailed a notification of the upcoming ap-
pointment that encourages them to use the visit prepar-
ation worksheet to note their questions and concerns for
the patient’s visit. Both patients and Care Partners will be
encouraged to share their questions and concerns with
one another before the patient’s visit.
Primary care visit summaries Within 1 week of a com-
pleted, qualifying primary care visit, the DEC will create
a visit summary using an automated template pro-
grammed into the electronic medical record (EMR). The
summary will include vital signs (including BP), recent
lab results (HbA1c or lipid levels), medication prescrip-
tions and changes, and a brief narrative section for
diabetes-related issues discussed. The summary will be
mailed to the patient, then 3 days later posted on the se-
cure study website for Care Partners and patients to
view or download. When a summary is posted online,
the Care Partner will receive an email notification with a
link to the summary.
Role of PACT clinical providers Although the interven-
tion is designed to ultimately be usable by medical
teams, participants’ clinicians will not be directly asked
to change their management of diabetes as part of the
intervention. Before beginning enrollment, study team
members will attend clinical staff meetings to provide an
overview of the intervention and practical tips on inter-
acting with family supporters who choose to call or at-
tend visits with the patient. A written summary of the
health information shared by the DEC at their initial ses-
sion with the dyad will be placed in the patient’s medical
record for their primary care team to view. This medical
record note will also serve to alert the medical team to
the Care Partner’s role and the fact that the patient has
given permission to share personal health information
with that supporter. The DEC will not change any com-
ponents of the patient’s diabetes management plan (e.g.,
no changes to medications, ordered tests, or consults). If
the patient asks the DEC about topics that are not in-
cluded in intervention session protocols, the DEC will
advise the patient to contact his/her nurse care manager
Table 2 Topics covered in automated interactive phone calls
Inquire whether patient worked on an action plan based on the
previous week’s call
Patient illness severe enough to interfere with diabetes management
Blood sugar levels: challenges to checking at home, low and high
levels, and symptoms
Blood pressure: challenges to checking at home, high and low
readings, and symptoms
Challenges to taking medications
Readiness to make a plan to quit smoking (if applicable)
New foot concerns
Summary of call, inquiry about importance to patient of potential
concerns identified
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for possible referral to an appropriate resource (such as
diabetes education classes).
Enhanced usual care (EUC)
Patients assigned to the EUC condition will receive usual
care for diabetes at VA facilities that have implemented
the VA PACT PCMH model. The fundamental compo-
nents of VA PACT care for high-risk diabetes are
co-management by a nurse or clinical pharmacist with
the primary care provider, coupled with referral to VA
chronic disease management support programs. The re-
cruitment primary care sites have fully staffed and func-
tional teams, defined roles and protocols for nurse care
manager/clinical pharmacist management of diabetes,
and available diabetes self-management classes, health
psychology services, weight loss programs, and auto-
mated telehealth programs to monitor home sugar and
BP results. Patients often receive visit summaries after
their primary care appointments. Study staff will also
provide patients in the EUC arm with general diabetes
management information via handbook and website as
well as home glucometers and BP monitors for patients
who want them. EUC patients will not be precluded
from involving family supporters in medical visits or
VA health programs. Thus, the outcomes of the
CO-IMPACT intervention will be compared to those of
a patient offered a highly resourced and functioning
PCMH, but without structured family support for
self-management, action planning, and engagement in
healthcare.
Measures and analysis
Data sources
Data will be obtained via patient in-person and family
supporter phone surveys at baseline and 12 months; pa-
tient and supporter 6 month surveys via telephone or
mail; patient BP and laboratory measurements at base-
line and 12 months; and patient pharmacy and clinical
encounter EMR data from periods 12 months prior to
baseline through 12 months beyond the intervention period.
Data from recruitment and coaching session logs and IVR
and website use will also be captured. See Additional file 6
for details on data management and security measures, safety
monitoring, and reporting of adverse events. Assessments
are described in detail below; assessment forms can be made
available upon request.
Blinding
Baseline survey assessments will be conducted by a study
staff person who is not aware of the participant’s study as-
signment, and all participant assessments will be conducted
by a staff person not involved in the delivery of the interven-
tion to the participant. Medical record data will be extracted
and main outcomes analyses conducted by analysts blinded
to group study assignment. Please see Additional file 7 for
more details on this and other aspects of the study protocol.
Patient outcome measures
Health behaviors and behavioral determinants The
study’s main outcome measure will be the Patient Acti-
vation Measure-13 (PAM-13) [51]. The PAM-13 has
been widely used to measure patient activation in longi-
tudinal studies and in clinical trials as a primary out-
come measure, and scores have been responsive to
intervention [52]. The PAM-13 is reliable (Cronbach
alpha 0.87) [53], and improvement in PAM-13 scores
has been linked to improvement in self-management be-
havior [54]. A 4- to 6-point change in the PAM is con-
sidered clinically significant [52, 55–57]. We will also
measure patient activation in medical visits with the Per-
ceived Efficacy in Patient-Physician Interactions (PEPPI-5)
[58]. Items include “I am confident in my ability…to get a
doctor to answer all of my questions” and “to get a doctor
to take my chief health concern seriously”. The PEPPI-5
has been validated against other self-efficacy and patient
satisfaction scales, and it is reliable (Cronbach alpha 0.92)
[59]. Table 3 lists other patient health behavior and behav-
ioral determinant measures that will be assessed.
Health risks To address the effect of CO-IMPACT on
patient health risks, our main measure will be the 5-year
UKPDS Risk Engine [42]. This score estimates the risk
of a coronary heart disease (CHD) event (fatal or
non-fatal myocardial infarction, or sudden death) specif-
ically among people with diabetes. The score compo-
nents include factors we hypothesize could be improved
by the intervention, including HbA1c, SBP, total choles-
terol/high-density lipoprotein (HDL) cholesterol ratio,
and smoking status. The score also includes age, sex,
race/ethnicity, and length of time since diabetes diagno-
sis. Using a cardiac risk score to measure risk factor
changes offers the advantages of quantifying the cumula-
tive impact of changes in multiple risk factors and trans-
lating changes in physiologic parameters to a risk
estimate that is meaningful to patients and policy
makers. For similar reasons, cardiac risk scores have
been successfully used as outcomes in multiple clinical
trials [60–64], and the UKPDS Risk Engine has been val-
idated in multiple populations [65].
HbA1c, lipid levels, BP, and smoking status will be ana-
lyzed independently as secondary health outcomes. We will
measure via survey patients’ frequency of hypoglycemia
and diabetes distress. Patients’ use of VA urgent care will
be extracted from the EMR for the period 12 months prior
to intervention start and during the 12-month study period,
supplemented by patient report of non-VA urgent care.
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Patient-supporter relationship and support quality
We will measure overall relationship quality for both pa-
tients and supporters (see Tables 3 and 4). Patient satis-
faction with overall quality of diabetes support received
and supporter use of autonomy-supportive communica-
tion will be assessed via patient survey. Supporters and
patients will be surveyed about concerns about health
privacy breaches.
Patient-provider relationship and patient satisfaction
with VA healthcare We will measure patient satisfaction
with VA primary care and their primary care provider,
using questions from the VA Consumer Assessment of
Healthcare Providers and Systems (CAHPS)-PCMH. We
will also ask about patient satisfaction with VA engage-
ment of their family supporters.
Family supporter outcomes
We will assess family supporter roles (e.g., helping to track
patient medication use at home) via surveys at baseline, 6,
and12 months. Family supporters’ self-efficacy for helping
patients with.
diabetes, supporter distress about the patient’s dia-
betes, and supporter distress about patient hypoglycemia
will be measured with adaptations from similar validated
Table 3 Details on selected patient measures
Construct Source Instrument(s) Baseline 6 mo. 12 mo.
Health behaviors and determinants
Activation Survey Patient Activation Measure (PAM-13) X X X
Activation in health encounters Survey Perceived Efficacy in Patient-Physician
Interactions (PEPPI-5)
X X X
Diabetes self-efficacy Survey Stanford Chronic Disease Self-Efficacy Scale [72] X X
Diabetes distress Survey Problem Areas in Diabetes Scale [73] X X
Diabetes self-management behavior (self-monitoring,
healthful eating, physical activity)
Survey Summary of Diabetes Self-Care Activities [74] X X X
Diabetes medication adherence EMR × 12
months
Cumulative medication gaps < 20% [75] X X
Smoking status Survey Items from the World Health Organization’s
Global Adult Tobacco Survey [76]
X X X
Physiologic and health outcomes
5-Year cardiac event risk survey +
physiologic
and lab testing
United Kingdom Prospective Diabetes Study
(UKPDS) 5 year cardiac risk score
X X
Glycemic control Venous
sample
HbA1c X X
Blood pressure Direct
measure
Systolic blood pressure, mean arterial pressure X X
Non-fasting lipid levels Venous
sample
Total cholesterol/HDL X X
Patient-supporter relationship and support quality
Patient-supporter relationship quality Survey Relationship Rating Form - Respect Subscale
[77]
X X
Patient satisfaction with diabetes social support Survey Diabetes Care Profile -Support Subscale [78] X X X
Supporter use of autonomy-supportive
communication
Survey Important Other Climate Questionnaire [79] X X
Potential moderators
Time with diabetes Survey X
Patient comorbidities EMR × 12
months
Charlson Comorbidity Index [80] X
Health literacy Survey Brief Health Literacy Screen [81] X
Current PTSD symptoms Survey Primary Care PTSD Screen for DSM5 [82] X
Depression and anxiety Survey Patient Health Questionnaire-4 [83] X X
EMR electronic medical record, HDL high-density lipoprotein, PTSD post-traumatic stress disorder, DSM Diagnostic and Statistical Manual of Mental
Health Disorders
Rosland et al. Trials  (2018) 19:394 Page 10 of 16
patient measures (Table 4). Caregiving burden will be
assessed with the reliable and validated Multidimen-
sional Caregiver Strain Index [66].
Patient and supporter moderators of effect
Theoretical patient moderators of intervention effects
that will be measured include (Table 3) sociodemo-
graphics (sex, age, education), baseline diabetes medica-
tion regimen, distance from VA site, comorbidities,
health literacy level, and comorbid depressive symp-
toms [67]. Additional moderators include whether the
patient and supporter live together, whether the sup-
porter has diabetes, supporter depressive symptoms,
baseline patient-supporter and patient-physician rela-
tionship quality, and whether family supporters attend
patient visits in person.
Intervention and control processes
Because the study is designed to determine whether add-
ing an incremental amount of attention towards patients’
family supporters leads to benefits to patients’ engage-
ment, health behaviors, and health outcomes, the study
will track rates of primary care and DEC visits, phone
calls, and letters; visit summaries; and use of telehealth
monitoring to evaluate differences in staff attention between
participant groups. Specifically, we will record the frequency
of each type of DEC contact with intervention-assigned par-
ticipants and the DEC time spent in preparation and execu-
tion of each contact. We will automatically capture the
outcomes of all IVR call attempts and the number of visits
to and downloads from the study website. For participants
in both arms, we will capture via EMR the number of com-
pleted primary care provider, nurse, and clinical pharmacist
encounters, occurring in person or by phone. We will ask
participants via survey whether they received visit summar-
ies after in-person primary care visits in both the interven-
tion and control conditions. We will tally consults entered
by primary care teams to diabetes risk-related programs as
well as patient (via EMR) and supporter (via survey) rates of
attendance. Finally, we will ask all patients and supporters
about the frequency of general discussions about diabetes,
pre-visit preparation discussions, and post-visit debriefing.
Intervention fidelity
A predetermined sequence (the first 10, then 10% of the
remaining by random number generation) of DEC initial
and telephone sessions will be recorded for review by the
study Principal Investigator (PI) and key investigators,
along with DEC-created documents. A checklist form will
facilitate standard fidelity reviews. Patient appointment
and IVR call records will be monitored regularly by study
staff for level of missed contact opportunities.
Retention and follow-up
Previous studies have found that, once recruited, dyads
have better study retention than patients participating
alone [37, 68]. Nevertheless, we will use several strat-
egies to maintain high retention, such as patient incen-
tives that cover cost of transportation for in-person
assessments at VA sites and staff travel to patients’ local
VA sites. We will offer patients the option to coordinate
in-person assessments with VA appointments. We will
offer family supporters phone and Internet options for
all study and intervention procedures. For patients re-
ceiving IVR calls, call completions are monitored, and if
patients miss their first call or three sequential calls, the
DEC calls to follow up, troubleshoot any issues prevent-
ing call completion, and encourage call completion. If
after several attempts we cannot complete a patient as-
sessment in person, we will ask the participant to
complete the survey assessment over the phone, with an
option for a short version of our assessment that priori-
tizes key measures: the Patient Activation Measure
(PAM-13), smoking status, diabetes self-management be-
haviors (taking medications, exercise, healthful eating),
and daily insulin doses.
Table 4 Details on selected supporter measures
Construct Source Instrument(s) Baseline 6 mo. 12 mo.
Behaviors and determinants
Supporter self-efficacy for helping patient
with diabetes mellitus care
Survey Adapted Stanford Chronic Disease Self-Efficacy Scale [72] X X X
Health and relationship outcomes
Caregiver burden Survey Caregiver Strain Index [66] X X
Supporter distress about patient’s diabetes Survey Adapted Problem Areas in Diabetes Scale [73] X X X
Adapted Fear of Hypoglycemia - Worry Subscale [84] X X
Patient-supporter relationship quality Survey Relationship Rating Form - Respect Subscale [77] X X
Potential moderators
Depression and anxiety Survey Patient Health Questionnaire-4 [83] X X
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Analysis plan
We will follow international guidelines for analysis and
reporting of clinical trials [69]. We will examine baseline
data for prognostically important differences across the two
study groups, such as patients’ age, race, comorbidities, and
baseline use of services. Although we do not anticipate any
imbalances, any baseline differences between experimental
arms will be included as covariates in analyses comparing
outcomes. Missing data will be imputed for non-outcome
measures, using multiple imputation methods. If we find
baseline variables to be associated with the loss to
follow-up, we will include those baseline variables as covari-
ates in models evaluating the intervention effect.
Unit of analysis and sample size calculation
Our main aims are to evaluate effects at the patient
level. Our sample size calculations are based on our pri-
mary outcome of patient activation, measured by the
PAM-13. Assuming that the PAM-13 was highly corre-
lated between baseline and 1 year (r = .70), we calculated
our sample size to provide a minimum of 80% power to
detect a between-group difference in PAM-13 change of
4.0, with a standard deviation of change of 13, and a
two-tailed alpha of 0.05. To achieve 80% power, a mini-
mum of 102 patients is needed in each group, for a total
sample size of 204. To allow for 15% attrition, we will
enroll 120 patients in each group, for a total of 240 pa-
tients. For our second aim, assuming the underlying cor-
relation between UKPDS at baseline and 1 year later is
.90, our sample size of 102 per group will provide more
than 80% power for detecting between-group differences
in predicted cardiac risk of 2.0% (standard deviation
(SD) = 12), which can be considered clinically significant
on a population level.
Primary analyses
All main analyses will be conducted using intention-to-treat
principles. Main analyses will be performed using hierarch-
ical linear models (HLMs) with scaled PAM scores (at base-
line and 1 year) and UKPDS scores (baseline and 1 year)
respectively as the outcomes. HLMs, or mixed models, in-
corporate both fixed and random effects. Fixed effects in-
clude treatment group, time, and whether the Care Partner
and participant lived together; all are dichotomous predic-
tors. Patient-level random effects will be included in the
model to account for correlations between patients’ repeated
measures over time.
Secondary analyses
As a supplementary analysis, we will analyze differences
in PAM score by interacting with four baseline PAM
strata, as a priori defined by the PAM scale developer.
As another supplemental analysis, the curvilinear trajec-
tory of the PAM-13 over time will be tested with growth
curve modeling using the PAM-13 score at 6 months in
addition to the score at baseline and at 1 year. Further,
random effects models will be used to examine differ-
ences in this trajectory based on treatment group. Se-
lected individual components of the UKPDS will be
analyzed independently as secondary health outcomes
using the same modeling strategy as outlined for the pri-
mary analyses above: HbA1c, SBP, non-HDL cholesterol,
and smoking status.
Mediators and moderators of intervention effect
We will use multivariable regression models to examine
potential mediators and moderators of intervention ef-
fects. We will introduce potential mediators to models
linking intervention condition to outcomes, examining
changes in the magnitude of the relationship between
the intervention and the outcomes before and after the
covariates are introduced. We will also use the Preacher
and Hayes bootstrapping method to examine potential
mediators to determine whether the mediation effect is
significant [70]. This is a non-parametric method that
can be used when the outcome violates assumptions of
normality. Potential mediators are specified in our theor-
etical model (Fig. 1) and include an index of family sup-
porter engagement in the intervention, composed of
measures of supporter participation in intervention ses-
sions and reported use of pre-visit preparation and
debriefing tools. Analyses of potential moderators will use
standard approaches to evaluate interactions between
these covariates and the intervention, which will include
plotting regression lines for high and low values of the
moderator variable using Stata routines [43]. Independent
variables and moderators will be centered before testing
interactions, so that multicollinearity between first-order
and higher-order terms will be minimized.
Process evaluation
We will use the RE-AIM framework [71] to guide this
analysis. To analyze the potential reach of the interven-
tion, we will calculate the proportion of patients with
diabetes who meet inclusion criteria and compare char-
acteristics of eligible and non-eligible dyads. Effective-
ness will be measured via our main outcomes and
differences in outcomes among key patient groups as de-
scribed above. We will evaluate adoption by examining
the characteristics of patients and supporters who de-
cline enrollment and their reasons for declining. We will
also examine retention/dropout from the study and rea-
sons, length/frequency of DEC sessions, percentage of
potential DEC sessions completed, and IVR call adher-
ence (percentage of attempted calls completed, number
of weeks adherent to calls).
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Discussion
The CO-IMPACT intervention takes a unique approach
to meeting the self-management support needs of
high-risk patients by empowering a family supporter to
help the patient with key self-management and health-
care navigation skills. The intervention will provide a
structured approach for clinical providers to engage fam-
ily supporters in patient self-management support, using
delivery methods designed to put minimal strain on cli-
nicians by maximizing automated and technologically
delivered information sharing with family supporters.
CO-IMPACT is innovative in its approach to increase
family supporter effectiveness through (1) training in ef-
fective ways to communicate with patients about their
healthcare, (2) training in effective ways to support pa-
tient engagement in their healthcare, and (3) providing
actionable and patient-specific health information. The
information-sharing and core skills are meant to enable
patients and family supporters to better take action on
recommendations made by their healthcare providers or
diabetes educators outside the CO-IMPACT program,
and can be used over time to respond to changing pa-
tient health situations and needs.
This study comparing CO-IMPACT to enhanced usual
care will allow us to assess whether providing an incremen-
tal amount of attention and training to family supporters
results in valuable improvements in patient health for pa-
tients who are at high risk for poor outcomes. The study
emphasizes outcomes that are patient-centered while also
evaluating impacts on patient-family and patient-provider
relationships. In addition, the techniques developed in con-
ducting this study will inform health system efforts to
screen for the presence of family members and other care-
givers involved in patient healthcare and to assess
family-related needs and outcomes relevant to care quality
and patient satisfaction.
CO-IMPACT is designed to tap into and harness the
potential of the large pool of family supporters to effect-
ively improve self-management and healthcare engage-
ment among patients with complex healthcare needs;
these family supporters include those family members
who live at a distance from the patient but are still regu-
larly involved in the patient’s healthcare. This study will
move beyond the status quo by focusing on families as the
context for, and as key players in, diabetes “self”-manage-
ment. If family members can more effectively support
healthcare, this would represent a novel source of support
that could be sustained over the long term needed to
meaningfully reduce diabetes complications. In addition,
because CO-IMPACT focuses on self-management and
patient communication skills that could be applied across
health conditions, the lessons learned in this study could
be easily applied to patients with other health conditions
or patients with multiple chronic conditions. If successful,
we expect this study to produce an evidence-based proto-
col and tools that engage patients with high-risk diabetes
and their family supporters in healthcare to help patients
achieve improved diabetes outcomes. Study results will be
disseminated through multiple communication strategies
including academic conferences and publications, profes-
sional societies such as healthcare provider and diabetes
educator organizations, healthcare system operations
leaders, and patient advocacy groups focused on diabetes
and veterans’ health. A summary of the results will also be
mailed directly to our participants. More generally, this
study will contribute to the growing body of knowledge
on how healthcare providers can most effectively engage
family supporters and caregivers in patients’ care to
optimize health management and outcomes.
Trial status
This protocol is version number 6, approved by the In-
stitutional Review Board (IRB) on September 11, 2016.
Recruitment began November 30, 2016, and recruitment
is expected to complete in June 2018.
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